ProCE Banner Activity

Key Updates in Lung Cancers From the ELCC 2024 Annual Meeting

Conference Coverage
Clinical Thought

Lung cancer experts highlight key studies from the 2024 European Lung Cancer Congress. CCO’s Independent Conference Coverage has the information you need to understand and integrate the latest data into your management of patients with NSCLC and SCLC.

Released: May 03, 2024

Expiration: May 02, 2025

Share

Faculty

Luis Paz-Ares

Luis Paz-Ares, MD, PhD

Chair of the Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor
Universidad Complutense de Madrid
Head of the Lung Cancer Unit
CNIO (Spanish National Cancer Research Center)
Madrid, Spain

Zofia Piotrowska

Zofia Piotrowska, MD, MHS

Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Faculty Disclosure

Primary Author

Luis Paz-Ares, MD, PhD

Chair of the Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor
Universidad Complutense de Madrid
Head of the Lung Cancer Unit
CNIO (Spanish National Cancer Research Center)
Madrid, Spain

Luis Paz-Ares, MD, PhD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Gilead, Lilly, Merck-Serono, MSD, Novartis, Pfizer, PharmaMar, Roche, Sanofi; grant/contract: AstraZeneca, Bristol Myers Squibb, MSD, Pfizer, PharmaMar; honoraria/speakers bureau: AstraZeneca, Janssen, Merck, Mirati, Sanofi.

Zofia Piotrowska, MD, MHS

Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Zofia Piotrowska, MD, MHS: consultant/advisor/speaker: AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Daiichi Sankyo, Genentech/Roche, Janssen, Lilly, Merck, Sanofi, Taiho, Takeda; researcher: AbbVie, AstraZeneca, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Roche, Spectrum, Takeda, Tesaro/GlaxoSmithKline.